BCL2L13 / Bcl-2-like protein 13 · IHC design guide

Design Immunohistochemistry for BCL2L13

Plan BCL2L13 chromogenic IHC using its selective cytoplasmic tissue profile (HPA tissue IHC). Compare staining with appropriate tissue controls and interpret weak signals cautiously because staining reliability is uncertain (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for BCL2L13 (IHC for BCL2L13): expected localisation Selective cytoplasmic tissue staining (HPA tissue IHC), antibody A06151, validated IHC image, and IHC protocol steps — Printable **BCL2L13** IHC protocol sheet — expected localisation Selective cytoplasmic tissue staining (HPA tissue IHC), antibody A06151, controls and protocol steps. Open the full BCL2L13 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

BCL2L13 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Selective cytoplasmic tissue staining (HPA tissue IHC)
	Staining pattern	Cytoplasmic staining in glands, hepatocytes and muscle (HPA tissue IHC)
	Antigen retrieval	Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen)
	Positive control ⓘ	Bone marrow+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific)
	Caveat	Staining reliability is uncertain (HPA tissue IHC)
	Regulation	Highest expression in heart, placenta and pancreas (UniProt)
	Isoform / epitope	3 isoforms; check epitope coverage across variants (UniProt)

Section 1

Recommended BCL2L13 IHC & IF Protocols

The catalog antibody protocol is followed by two published BCL2L13 IHC protocols using paraffin sections and chromogenic detection (PMC10475114; PMC8247248).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Tissue sections; selected-image fixative not specified (standard IHC workflow)
Fixation	Image fixative and duration unreported (datasheet A06151); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-BCL2L13, 10 μg/mL (datasheet A06151)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	BCL2L13-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: Medium). HPA tissue profile: Selective cytoplasmic expression in salivary glands, exocrine pancreas, hepatocytes, muscle tissues and a subsets of lymphoid tissues. No signal in the no-primary control.

💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval setting); compare citrate retrieval if needed (PMC10475114).

Section 2

What Is the Expected BCL2L13 Staining Pattern?

BCL2L13 is annotated at the mitochondrial membrane, with a transmembrane segment at residues 460–480; UniProt also lists the nucleus (UniProt Q9BXK5 topology and subcellular location). In tissue IHC, expect selective cytoplasmic staining, including in exocrine pancreas, hepatocytes, muscle tissues and subsets of lymphoid tissues (HPA: tissue IHC profile). Treat that pattern as provisional: HPA rates tissue IHC reliability Uncertain because staining and RNA expression have medium consistency (HPA: reliability).

What am I looking at on my slide?
Selective cytoplasmic staining in cardiomyocytes or skeletal myocytes, with adjacent cells differing in intensity.	This fits the reported tissue distribution: both cell types show Medium staining (HPA: heart muscle cardiomyocytes; skeletal muscle myocytes). Evaluate cell identity and compartment together; intensity alone does not establish specificity, especially with the Uncertain tissue IHC rating (HPA: reliability).
Predominantly extracellular staining, or a uniform deposit over tissue regardless of cell boundaries.	This does not fit the selective cytoplasmic tissue pattern (HPA: tissue IHC profile). Check section quality, chromogen deposition and wash performance as general IHC practice. Nuclear staining needs separate review: UniProt also annotates the nucleus, while HPA's tissue IHC profile emphasizes cytoplasm (UniProt Q9BXK5 subcellular location; HPA: tissue IHC profile).
Strong signal in adipocytes or bronchial respiratory epithelium while the expected cytoplasmic cell pattern is absent.	Both cell populations are reported Not detected in the supplied tissue IHC record (HPA: adipose tissue adipocytes; bronchus respiratory epithelial cells). Consider antibody cross-reactivity or endogenous detection activity; compare primary-omission and detection controls as general IHC practice before assigning the signal to BCL2L13.
Low-level color covers many cell types and tissue spaces, obscuring cell borders.	Diffuse background prevents a defensible cell-level call against HPA's selective cytoplasmic profile (HPA: tissue IHC profile). Review blocking, washing, detection exposure and section handling as general IHC practice. Do not interpret a broad haze as evidence of ubiquitous protein staining simply because UniProt describes broad tissue expression (UniProt Q9BXK5 tissue specificity).
No signal in heart-muscle cardiomyocytes under conditions that stain other targets.	HPA reports Medium cardiomyocyte staining, making this a useful comparison tissue, but its BCL2L13 IHC evidence remains Uncertain (HPA: heart muscle cardiomyocytes; reliability). Check the assay's positive control and detection steps first; a negative result alone cannot prove BCL2L13 is absent (general IHC practice).

💡Expected BCL2L13 appearanceCall a result compatible when selective cytoplasmic signal of roughly Medium intensity appears in cardiomyocytes or skeletal myocytes (HPA: heart muscle cardiomyocytes; skeletal muscle myocytes); widespread extracellular color or strong staining in reported Not detected cells is suspect (HPA: tissue IHC profile; adipose tissue adipocytes).

How each factor affects the staining
Tissue and cell selection	HPA reports selective cytoplasmic staining in salivary glands, exocrine pancreas, hepatocytes, muscle tissues and subsets of lymphoid tissues, despite low tissue RNA specificity (HPA: tissue IHC profile; RNA specificity). Choose comparison regions by identified cell type; whole-section averages can conceal that selectivity (general IHC practice).
Membrane topology and compartment	The 460–480 transmembrane segment supports a membrane-associated mitochondrial expectation (UniProt Q9BXK5 topology and subcellular location). HPA's tissue IHC description is cytoplasmic, without resolving mitochondria in paraffin sections (HPA: tissue IHC profile). Do not require visible mitochondrial puncta to score chromogenic IHC.
Isoforms and epitope coverage	UniProt lists 3 isoforms and one annotated chain spanning residues 1–485 (UniProt Q9BXK5 isoforms and processing). The payload gives no antibody epitope, isoform-specific staining or tissue-level processing result; check the antibody's epitope documentation before making any isoform claim.
Strength of tissue IHC evidence	Both antibodies with a reported IHC status here, HPA030994 and CAB002052, are rated Uncertain (HPA: antibody validation). HPA describes medium consistency between staining and RNA data (HPA: reliability). Use morphology and independent controls when interpreting a weak or unexpected stain (general IHC practice).
IF/ICC Q&A: should puncta be expected?	Yes for IF/ICC interpretation: HPA reports enhanced mitochondrial localization and lists approved ICC evidence for HPA030994 and HPA050377 (HPA: subcellular summary; antibody validation). That supports a mitochondrial IF expectation; it does not upgrade the Uncertain tissue IHC rating or set an IHC protocol (HPA: reliability).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Cardiomyocytes remain blank in a completed chromogenic run.	The reported comparison population has Medium staining, but IHC reliability is Uncertain; a blank slide does not identify the failed step (HPA: heart muscle cardiomyocytes; reliability).	Confirm tissue identity, a working detection control, primary incubation and reagent condition; then review retrieval against the antibody's IHC instructions (general IHC practice). Do not assign a BCL2L13-specific retrieval requirement from these sources.
Color appears across the slide rather than within selected cells.	The distribution conflicts with selective cytoplasmic tissue staining (HPA: tissue IHC profile); excess detection or incomplete washing can produce background (general IHC practice).	Compare a primary-omission control; review blocking, washes and chromogen development (general IHC practice). Reassess only signal that follows identifiable cells and compartments (HPA: tissue IHC profile).
Adipocytes or bronchial respiratory epithelial cells stain strongly.	Those populations are reported Not detected (HPA: adipose tissue adipocytes; bronchus respiratory epithelial cells). Cross-reactivity or endogenous detection activity is possible (general IHC practice).	Inspect a primary-omission control and the detection system's endogenous-activity control; compare with a cell population reported positive in the same run (general IHC practice; HPA: heart muscle cardiomyocytes).
A strong nuclear-only pattern appears without selective cytoplasmic staining.	UniProt annotates the nucleus, so nuclear signal cannot be dismissed categorically; HPA's tissue IHC profile instead describes selective cytoplasmic expression (UniProt Q9BXK5 subcellular location; HPA: tissue IHC profile).	Check whether nuclear staining follows plausible cell types and whether controls also stain nuclei (general IHC practice). Report the discrepancy explicitly; do not call nuclear-only tissue staining validated by HPA.
Signal is weaker in one tissue region than another.	HPA describes selective expression and reports different cell populations at Medium, Low or Not detected levels (HPA: tissue IHC profile; tissue cell-level entries). Region-wide comparison can mix distinct cell types.	Compare the same identified cell type across matched regions and score localization alongside intensity (general IHC practice). Use HPA's cell-level entries as context, while retaining its Uncertain reliability caveat (HPA: reliability).
IF/ICC shows mitochondrial signal, but chromogenic IHC looks broadly cytoplasmic.	HPA reports enhanced mitochondrial localization in ICC-IF and selective cytoplasmic staining in tissue IHC (HPA: subcellular summary; tissue IHC profile). The two observations have different spatial resolution (general microscopy practice).	Interpret each image within its application: assess cell-level cytoplasmic selectivity for tissue IHC and mitochondrial localization for IF/ICC (HPA: tissue IHC profile; subcellular summary). Keep the tissue IHC Uncertain rating in the report (HPA: reliability).

Source: UniProt Q9BXK5 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing BCL2L13 staining

A06151 · IHCImmunohistochemistry of Bcl-rambo in human heart tissue with Bcl-rambo antibody at 10 μg/mL.

A06151 · IFImmunofluorescence of Bcl-rambo in Human Heart cells with Bcl-rambo antibody at 20 μg/mL.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000099968-BCL2L13/tissue/cerebral+cortex#imid_11044959

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000099968-BCL2L13/tissue/colon#imid_11048909

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000099968-BCL2L13/tissue/liver#imid_11048910

HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000099968-BCL2L13/tissue/pancreas#imid_11048869

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA030994; green = BCL2L13, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for BCL2L13 IHC & IF

🧪Run heart muscle first: cardiomyocytes should stain (HPA: Medium in cardiomyocytes). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); on the heart slide, cells without specific staining should show counterstain and background only, although these HPA rows do not establish a particular cardiac cell type as an internal negative.

Positive control tissue: Bone marrow (Hematopoietic cells, HPA Medium)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BCL2L13 in A-431, HaCaT, MCF-7, U2OS, with annotated localisation: Mitochondria (enhanced) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species, clonality, and concentration; and, where available, BCL2L13 knockout tissue or peptide blocking as a biological specificity control (standard IHC practice). For chromogenic detection in heart sections, quench endogenous peroxidase before HRP detection and check for background from blood-containing areas (standard IHC practice).

⚠️Feasibility: A target-specific fixation window and fixation effect are unreported in the supplied evidence; the selected tissue-IHC caption also leaves the fixative unreported (selected SKU A06151 caption). Retrieval dependence is unreported, so optimize antigen retrieval on paraffin sections with the catalog antibody (standard IHC practice). Frozen-section performance and relative ease are unreported; ICC/IF localization is supported by images from A-431, HaCaT, MCF-7, and U2OS cells (HPA: mitochondria, enhanced), while heart sections require attention to endogenous peroxidase in chromogenic IHC (standard IHC practice).

HPA tissue IHC evidence for BCL2L13

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Bone marrow	Hematopoietic cells	Medium	Protein (IHC)	HPA →
Breast	Myoepithelial cells	Medium	Protein (IHC)	HPA →
Cerebral cortex	Glial cells	Medium	Protein (IHC)	HPA →
Heart muscle	Cardiomyocytes	Medium	Protein (IHC)	HPA →
Lymph node	Non-germinal center cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	Not detected	Protein (IHC)	HPA →
Caudate	Glial cells	Not detected	Protein (IHC)	HPA →
Cerebellum	Cells in granular layer	Not detected	Protein (IHC)	HPA →

Section 3

Advanced BCL2L13 IHC Tips

Troubleshoot BCL2L13 staining in paraffin sections by checking retrieval, controls, subcellular pattern and scoring before interpreting chromogenic signal.

How should I troubleshoot weak BCL2L13 staining after antigen retrieval?

Use Tris-EDTA pH 9.0 heat-induced retrieval at 95–98 °C for 20 min for BCL2L13 paraffin IHC (page retrieval setting). Keep section thickness, cooling and staining conditions consistent when comparing runs (standard IHC practice). If staining remains weak, test a second retrieval condition on adjacent sections as a fallback, while retaining the specified condition as the reference (standard IHC practice). Include a heart section as a comparison: the selected antibody has a human heart tissue-IHC image at 10 µg/mL, although its fixative is unreported (caption: A06151). Compare signal with negative controls before increasing antibody concentration, because tissue-IHC staining has uncertain reliability (HPA: Uncertain).

Could fixation explain weak or uneven BCL2L13 staining?

BCL2L13-specific sensitivity to fixation is unknown from the supplied evidence; the selected tissue-IHC caption does not state a fixative (caption: A06151). Record fixation reagent, duration and time before fixation for every specimen, then compare sections processed together (standard IHC practice). For a troubleshooting comparison, hold retrieval at Tris-EDTA pH 9.0, 95–98 °C for 20 min while varying only specimen preparation (page retrieval setting; standard IHC practice). Check whether weak regions also show poor morphology or uneven staining of a suitable control antigen (standard IHC practice). Neither tissue expression patterns nor protein topology establishes a fixation effect for BCL2L13 (HPA: tissue IHC; UniProt Q9BXK5 topology).

What staining pattern is plausible for BCL2L13 in tissue sections?

Assess BCL2L13 primarily for cytoplasmic staining with a mitochondrial distribution; nuclear localisation is also recorded, so document nuclear signal separately (HPA: tissue IHC; HPA: subcellular; UniProt Q9BXK5). A chromogenic deposit cannot by itself resolve individual mitochondria, so avoid calling fine puncta definitive mitochondrial localisation (standard IHC practice). Heart muscle is a useful reference because cardiomyocytes show medium tissue-IHC staining, and the selected antibody has a human heart image at 10 µg/mL (HPA: heart muscle; caption: A06151). Compare the suspected cellular pattern across adjacent sections and negative controls under the same retrieval and detection conditions (standard IHC practice). Record cytoplasmic and nuclear scores separately if both patterns persist (standard IHC practice).

Could isoforms or epitope accessibility change the IHC result?

BCL2L13 has 3 annotated isoforms, but the supplied antibody evidence does not identify an epitope or establish isoform coverage (UniProt Q9BXK5; caption: A06151). Its annotated transmembrane segment spans residues 460–480; the supplied topology does not establish which side contains the antibody epitope (UniProt Q9BXK5 topology). Phosphorylated residues include 38, 259 and 261, yet no supplied evidence links those modifications to staining changes (UniProt Q9BXK5 modified residues). If sections disagree, document the antibody's mapped epitope if available and compare controls across retrieval runs (standard IHC practice). Do not assign isoform-specific expression from chromogenic intensity without isoform-specific validation (standard IHC practice).

How can IF help assess an ambiguous chromogenic IHC pattern?

Use IF as a separate localisation check: BCL2L13 is reported at mitochondria, with ICC/IF images listed for A-431, HaCaT, MCF-7 and U2OS cells (HPA: subcellular). Multiplex with a marker for the cell type expected in the IHC section, such as a cardiomyocyte marker when examining heart muscle (HPA: heart muscle; standard IF practice). Choose a fluorophore in a channel with low tissue autofluorescence and inspect unstained tissue in that channel first (standard IF practice). Permeabilise according to the antibody epitope's membrane-facing side; that side is not established by the supplied topology or caption (UniProt Q9BXK5 topology; caption: A06151). Compare cellular localisation with IHC, without treating IF intensity as a direct chromogenic score (standard IF/IHC practice).

How do I reduce diffuse or misleading BCL2L13 chromogenic background?

First inspect a no-primary section for signal from the detection system and tissue pigments before attributing diffuse deposit to BCL2L13 (standard IHC practice). With peroxidase-based detection, apply a peroxidase block and use DAB development and counterstaining consistently across samples (standard IHC practice). Titrate the catalog antibody around the image condition of 10 µg/mL, recording each concentration and development time; the image does not establish an optimal dilution for other specimens (caption: A06151; standard IHC practice). Check whether background tracks tissue edges, folds or necrotic areas rather than intact cells (standard IHC practice). Require reproducible cellular staining over controls, especially because tissue-IHC reliability is uncertain (HPA: Uncertain; standard IHC practice).

What is a defensible way to score BCL2L13 IHC? ⚠ ANSWER MARKED FOR VERIFICATION

Define the analysed cell population and compartment before scoring, because tissue-IHC expression varies by cell type and BCL2L13 has mitochondrial and reported nuclear localisation (HPA: tissue IHC; UniProt Q9BXK5). Record the percentage of positive intact cells and staining intensity, then calculate an H-score on a 0–300 scale if ordinal intensity scoring is appropriate (standard IHC practice). For sparse positive populations, report positive cells per mm² and normalise to the area of viable, analysable tissue (standard IHC practice). Keep retrieval, imaging and DAB development consistent across comparisons (standard IHC practice). Report cytoplasmic and nuclear results separately and include negative-control background in the scoring threshold (standard IHC practice).

When should an apparent BCL2L13-positive section be questioned?

Question signal confined to section edges, folds or necrotic regions, and compare it with a no-primary control for endogenous enzyme or pigment effects (standard IHC practice). A cellular cytoplasmic pattern is plausible, while mitochondrial localisation needs higher-resolution corroboration; nuclear localisation is also recorded (HPA: tissue IHC; HPA: subcellular; UniProt Q9BXK5). Check the stained cell type: cardiomyocytes show medium staining, whereas adipocytes are listed as not detected in the tissue-IHC dataset (HPA: heart muscle; HPA: adipose tissue). Treat an unexpected compartment or cell population as a validation prompt, not automatic evidence of absence or artefact (standard IHC practice). Interpret intensity cautiously because antibody staining and RNA data have medium consistency (HPA: Uncertain).

Boster reagents

Best BCL2L13 / Bcl-2-like protein 13 IHC Antibodies

A06151 has human heart IHC and IF images (catalog image captions) and lists Human, Mouse and Rat reactivity (catalog applications and reactivity); the IHC specimen’s fixative is unreported (catalog IHC caption).

Real IHC data Immunohistochemistry of Bcl-rambo in human heart tissue with Bcl-rambo antibody at 10 μg/mL.

Anti-Bcl-rambo BCL2L13 Antibody

Cat # A06151

View product →

A06151 will render with an IHC image of human heart tissue at 10 μg/mL (catalog IHC caption). Its IF image shows human heart cells at 20 μg/mL (catalog IF caption), and its application list includes IHC-P and IF (catalog applications).

Which to pick: Choose A06151 for paraffin-section tissue IHC because IHC-P is listed and its own IHC caption shows human heart tissue at 10 μg/mL; the caption does not report the fixative (catalog applications; catalog IHC caption). For IF/ICC, start with A06151 because IF is listed and its own IF caption shows human heart cells at 20 μg/mL (catalog applications; catalog IF caption). For Mouse or Rat IHC, both A06151 and the polyclonal A06151-1 list those species and IHC among their applications, but the supplied IHC image documents Human tissue only for A06151, while A06151-1 has no supplied IHC image (catalog reactivity, applications, dilution details and image captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9BXK5 (B2L13_HUMAN, Bcl-2-like protein 13).
Human Protein Atlas. BCL2L13 tissue IHC expression (reliability: Uncertain).
Human Protein Atlas. BCL2L13 subcellular location (ICC-IF): Localized to the mitochondria..
Human Protein Atlas. BCL2L13 antibody validation summary (3 antibodies).
BCL2L13 promotes mitophagy through DNM1L-mediated mitochondrial fission in glioblastoma. Cell death & disease 2023 — PMC10475114.
Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma. Cancer cell international 2021 — PMC8247248.
BCL2L13 at endoplasmic reticulum-mitochondria contact sites regulates calcium homeostasis to maintain skeletal muscle function. iScience 2024 — PMC11340602.
PubMed PMID:11262395 — UniProt-cited evidence.
PubMed PMID:11381032 — UniProt-cited evidence.
PubMed PMID:15461802 — UniProt-cited evidence.